Tonix Pharmaceuticals Holding (TNXP) Capital Expenditures (2011 - 2026)

Tonix Pharmaceuticals Holding's Capital Expenditures history runs 16 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 28100.0% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 27983.33% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 2707.5% from the prior year.
• Capital Expenditures eased to $1.7 million in Q1 2026 per TNXP's latest filing, from $1.9 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $20.2 million in Q1 2022 and bottomed at -$889000.0 in Q3 2023.
• The 5-year median for Capital Expenditures is $885000.0 (2023), against an average of $3.8 million.
• Across the five-year window, Capital Expenditures slumped 110.08% in 2023 and soared 62366.67% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $4.7 million in 2022, then surged by 63.13% to $7.6 million in 2023, then sank by 99.96% to $3000.0 in 2024, then surged by 62366.67% to $1.9 million in 2025, then dropped by 9.71% to $1.7 million in 2026.
• Per Business Quant, the three latest TNXP Capital Expenditures figures stand at $1.7 million (Q1 2026), $1.9 million (Q4 2025), and $969000.0 (Q3 2025).